These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23340294)

  • 1. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
    Schott AF; Landis MD; Dontu G; Griffith KA; Layman RM; Krop I; Paskett LA; Wong H; Dobrolecki LE; Lewis MT; Froehlich AM; Paranilam J; Hayes DF; Wicha MS; Chang JC
    Clin Cancer Res; 2013 Mar; 19(6):1512-24. PubMed ID: 23340294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
    Cook N; Basu B; Smith DM; Gopinathan A; Evans J; Steward WP; Palmer D; Propper D; Venugopal B; Hategan M; Anthoney DA; Hampson LV; Nebozhyn M; Tuveson D; Farmer-Hall H; Turner H; McLeod R; Halford S; Jodrell D
    Br J Cancer; 2018 Mar; 118(6):793-801. PubMed ID: 29438372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
    Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An accessible pharmacodynamic transcriptional biomarker for notch target engagement.
    Tanis KQ; Podtelezhnikov AA; Blackman SC; Hing J; Railkar RA; Lunceford J; Klappenbach JA; Wei B; Harman A; Camargo LM; Shah S; Finney EM; Hardwick JS; Loboda A; Watters J; Bergstrom DA; Demuth T; Herman GA; Strack PR; Iannone R
    Clin Pharmacol Ther; 2016 Apr; 99(4):370-80. PubMed ID: 26765077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
    McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
    Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
    Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
    Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.
    Wang D; Xu J; Liu B; He X; Zhou L; Hu X; Qiao F; Zhang A; Xu X; Zhang H; Wicha MS; Zhang L; Shao ZM; Liu S
    Cell Death Differ; 2018 Feb; 25(2):330-339. PubMed ID: 29027990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
    Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
    Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
    Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
    Luke JJ; LoRusso P; Shapiro GI; Krivoshik A; Schuster R; Yamazaki T; Arai Y; Fakhoury A; Dmuchowski C; Infante JR
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):549-58. PubMed ID: 26811179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
    Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
    Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity.
    D'Angelo RC; Ouzounova M; Davis A; Choi D; Tchuenkam SM; Kim G; Luther T; Quraishi AA; Senbabaoglu Y; Conley SJ; Clouthier SG; Hassan KA; Wicha MS; Korkaya H
    Mol Cancer Ther; 2015 Mar; 14(3):779-787. PubMed ID: 25673823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Notch signaling pathway enhanced the radiosensitivity of breast cancer cells.
    Peng JH; Wang XL; Ran L; Song JL; Zhang ZT; Liu X; Li HY
    J Cell Biochem; 2018 Nov; 119(10):8398-8409. PubMed ID: 29904942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.